PTGX Overview

Company Profile

Related stocks

CAI • United States

Caris Life Sciences, Inc.

29.7 USD

8.39B USD 1Y -16.5%

ARWR • United States

Arrowhead Pharmaceuticals, Inc.

62.75 USD

8.84B USD 1Y +64.4%

TGTX • United States

TG Therapeutics, Inc.

55.37 USD

8.48B USD 1Y +49.2%

TECH • United States

Bio-Techne Corp

72.46 USD

11.36B USD 1Y +19.6%

MANE • United States

Veradermics, Incorporated

130.9 USD

5.47B USD

PCVX • United States

Vaxcyte, Inc.

71.38 USD

10.62B USD 1Y +59.6%

NUVL • United States

Nuvalent, Inc.

123.96 USD

9.79B USD

KYMR • United States

Kymera Therapeutics, Inc.

112.4 USD

9.35B USD 1Y +94.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

4 Metrics

Country

Region

Sector

Industry

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

78.9% p.a.

Max Drawdown (5Y)

-81.0%

Sharpe Ratio (5Y)

0.61

Beta Factor

1.52

Size Class

Mid Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.

High market risk: Beta of 1.52 indicates above-average volatility compared to the broader market.

🔴 High valuation risk: Avg P/E of 139.5 (Elevated multiple compression risk)

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (78.9% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -85.8% in the extended horizon.